XML 61 R50.htm IDEA: XBRL DOCUMENT v3.20.2
Net Income (Loss) Per Share - Schedule of Diluted Net Loss Per Share (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Numerator        
Net income (loss) attributed to Inovio Pharmaceuticals, Inc. (numerator for use in basic net income (loss) per share) $ 19,171,336 $ (23,090,693) $ (142,072,777) $ (81,697,181)
Adjustment for decrease in fair value of derivative liability and interest expense 0 (2,177,250) 0 0
Numerator for use in diluted income (loss) per share $ 19,171,336 $ (25,267,943) $ (142,072,777) $ (81,697,181)
Denominator        
Weighted average number of common shares outstanding (denominator for use in basic net income (loss per share) (in shares) 165,355,540 99,007,985 148,656,454 98,204,375
Effect of dilutive potential common shares (in shares) 9,020,862 3,799,071 0 0
Denominator for use in diluted net income (loss) per share (in shares) 174,376,402 102,807,056 148,656,454 98,204,375
Net income (loss) per share, diluted (in dollars per share) $ 0.11 $ (0.25) $ (0.96) $ (0.83)
Net income (loss) per share, basic (in dollars per share) $ 0.12 $ (0.23) $ (0.96) $ (0.83)